Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRS-300
- Development stage
- Unknown
- Lead developer
- Pieris Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
PRS-300 is an investigational Anticalin-based protein therapeutic from Pieris Pharmaceuticals' proprietary PRS-300 Series, designed as a bispecific or multispecific fusion protein targeting CTLA-4, an immunomodulatory checkpoint protein, to enhance anti-tumor immune responses. Developed using Pieris' Anticalin platform derived from human lipocalins, it aims to compete with marketed CTLA-4 inhibitors like ipilimumab while offering improved therapeutic profiles through its low molecular-weight design for potentially better tumor penetration and reduced toxicity. The program focuses on immuno-oncology applications, with preclinical efforts highlighting its role in cancer immunotherapy.
- Other names
- PRS 300PRS300PRS-300
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on PRS-300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRS-300.